Uncommon yeast infections in hematological patients: From diagnosis to treatment

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 11, 2011, Pages 1067-1075

  Caira, Morena ^a   Trecarichi, Enrico Maria ^a   Tumbarello, Mario ^a   Leone, Giuseppe ^a   Pagano, Livio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Blastoschizomyces; cryptococcosis; Rhodotorula spp.; trichosporonosis; yeast infection

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; HEMOPOIETIC GROWTH FACTOR; ISAVUCONAZOLE; ITRACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

BLOOD CULTURE; CANCER PATIENT; CATHETER REMOVAL; CLINICAL FEATURE; CRYPTOCOCCOSIS; DIPODASCUS CAPITATUS INFECTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; DRUG MEGADOSE; FALSE POSITIVE RESULT; FUNGEMIA; GRANULOCYTE TRANSFUSION; HANSENULA INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION PREVENTION; LUNG MYCOSIS; MALASSEZIA DERMATITIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PULMONARY CRYPTOCOCCOSIS; REVIEW; RHODOTORULA FUNGEMIA; SACCHAROMYCES INFECTION; SENSITIVITY AND SPECIFICITY; SYSTEMIC MYCOSIS; TREATMENT OUTCOME; TRICHOSPORONOSIS;

ANTIFUNGAL AGENTS; BLASTOMYCES; CRYPTOCOCCUS; ECHINOCANDINS; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOLOGICAL TYPING TECHNIQUES; MYCOSES; SURVIVAL RATE; TRIAZOLES; TRICHOSPORON;

EID: 80155177953     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.124     Document Type: Review

References (91)

1. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin. Infect. Dis. 45(9), 1161-1170 (2007).
2. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study. Clin. Infect. Dis. 45, 1161-1170 (2007).
3. de Pauw BE. What are fungal infections? Mediterr. J. Hematol. Infect. Dis. 3(1), e2011001 (2011).
4. Caira M, Mancinelli M, Leone G, Pagano L. Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Med. Mycol. 49 (Suppl. 1), S13-S16 (2011).
5. Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 36(4), 296-313 (2008).
6. Caira M, Girmenia C, Fadda RM et al. Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk? Eur. J. Haematol. 81(3), 242-243 (2008).
7. Shang ST, Yang YS, Peng MY. Nosocomial Trichosporon asahii fungemia in a patient with secondary hemochromatosis: a rare case report. J. Microbiol. Immunol. Infect. 43(1), 77-80 (2010).
8. Richardson M. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect. 14(Suppl. 4), 5-24 (2008).
9. Enoch DA, Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol. 55(Pt 7), 809-818 (2006).
10. Caira M, Trecarichi EM, Mancinelli M, Leone G, Pagano L. Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment. Expert Rev. Antinfect. Ther. 9(7), 881-892 (2011).
11. Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J. Clin. Microbiol. 43(4), 1818-1828 (2005).
12. Pagano L, Fianchi L, Caramatti C et al. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMAinfection. Haematologica 89(7), 852-856 (2004).
13. Chagas-Neto TC, Chaves GM, Colombo AL. Update on the genus Trichosporon. Mycopathologia 166(3), 121-132 (2008).
14. Winston DJ, Balsley GE, Rhodes J, Linné SR. Disseminated Trichosporon capitatum infection in an immunosuppressed host. Arch. Intern. Med. 137(9), 1192-1195 (1977).
15. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1), 48-66 (2004).
16. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin. Microbiol. Infect. 7(Suppl. 2), 8-24 (2001).
17. Pagano L, Caira M, Fianchi L. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. Ann. Med. 37(4), 259-269 (2005).
18. Ruan SY, Chien JY, Hsueh PR. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin. Infect. Dis. 49(1), e11-e17 (2009).
19. Kontoyiannis DP, Torres HA, Chagua M et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand. J. Infect. Dis. 36(8), 564-569 (2004).
20. Miyakoshi S, Kusumi E, Matsumura T et al. Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. Biol. Blood Marrow Transplant. 13(7), 771-777 (2007).
21. Suzuki K, Nakase K, Kyo T et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur. J. Haematol. 84(5), 441-447 (2010).
22. Chagas-Neto TC, Chaves GM, Melo AS, Colombo AL. Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing. J. Clin. Microbiol. 47(4), 1074-1081 (2009).
23. Lacasse A, Cleveland KO. Trichosporon mucoides fungemia in a liver transplant recipient: case report and review. Transpl. Infect. Dis. 11(2), 155-159 (2009).
24. Netsvyetayeva I, Swoboda-Kopeć E, Paczek L et al. Trichosporon asahii as a prospective pathogen in solid organ transplant recipients. Mycoses 52(3), 263-265 (2009).
25. Gross JW, Kan VL. Trichosporon asahii infection in an advanced AIDS patient and literature review. AIDS 22(6), 793-795 (2008).
26. Jian DY, Yang WC, Chen TW, Lin CC. Trichosporon asahii following polymicrobial infection in peritoneal dialysis-associated peritonitis. Perit. Dial. Int. 28(1), 100-101 (2008).
27. Antachopoulos C, Papakonstantinou E, Dotis J et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J. Pediatr. Hematol. Oncol. 27(5), 283-285 (2005).
28. Ebright JR, Fairfax MR, Vazquez JA. Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient without cancer or neutropenia. Clin. Infect. Dis. 33(5), E28-E30 (2001).
29. O'Gorman C, McMullan R, Webb CH, Bedi A. Trichosporon asahii. Blood-stream infection in a non-cancer patient receiving combination antifungal therapy. Ulster Med. J. 75(3), 226-227 (2006).
30. Kim YJ, Kim SI, Kim YR, Park YM, Park YJ, Kang MW. Successful treatment of septic shock with purpura fulminans caused by Trichosporon asahii in an immunocompetent patient. Ann. Clin. Lab. Sci. 37(4), 366-369 (2007).
31. Rastogi VL, Nirwan PS. Invasive trichosporonosis due to Trichosporon asahii in a non-immunocompromised host: a rare case report. Indian J. Med. Microbiol. 25(1), 59-61 (2007).
32. Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D'Antonio D, Piccolomini R. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance. Antimicrob. Agents Chemother. 50(10), 3269-3276 (2006).
33. Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect. Dis. 11(2), 142-151 (2011).
34. Nagai H, Yamakami Y, Hashimoto A, Tokimatsu I, Nasu M. PCR detection of DNA specific for Trichosporon species in serum of patients with disseminated trichosporonosis. J. Clin. Microbiol. 37(3), 694-699 (1999).
35. Sugita T, Nakajima M, Ikeda R, Niki Y, Matsushima T, Shinoda T. A nested PCR assay to detect DNA in sera for the diagnosis of deep-seated trichosporonosis. Microbiol. Immunol. 45(2), 143-148 (2001).
36. Melcher GP, Reed KD, Rinaldi MG, Lee JW, Pizzo PA, Walsh TJ. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J. Clin. Microbiol. 29(1), 192-196 (1991).
37. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev. 24(2), 51-61 (2010).
38. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. 46(4), 1144-1146 (2002).
39. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis. 42(6), 753-757 (2006).
40. Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin. Infect. Dis. 43(4), e39-e41 (2006).
41. Taj-Aldeen SJ, Al-Ansari N, El Shafei S et al. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J. Clin. Microbiol. 47(6), 1791-1799 (2009).
42. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 47(1), 117-123 (2009).
43. Anaissie EJ, Hachem R, Karyotakis NC et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis. Antimicrob. Agents Chemother. 38(11), 2541-2544 (1994).
44. Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur. J. Clin. Microbiol. Infect. Dis. 26(11), 843-845 (2007).
45. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20(4), 121-136 (2003).
46. Akagi T, Yamaguti K, Kawamura T, Nakumura T, Kubo K, Takemori H. Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk. Lymphoma 47(6), 1182-1183 (2006).
47. Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 36(1), 68-70 (2008).
48. Li H, Lu Q, Wan Z, Zhang J. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii. Int. J. Antimicrob. Agents 35(6), 550-552 (2010).
49. Li H, Qiao J, Wan Z, Zhang J. In vitro interaction of itraconazole with amphotericin B, caspofungin, and terbinafine against clinical isolates of Trichosporon asahii. Mycopathologia 171(5), 345-348 (2010).
50. Thompson GR 3rd, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J. Antimicrob. Chemother. 64(1), 79-83 (2009).
51. Guinea J, Recio S, Escribano P, Peláez T, Gama B, Bouza E. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob. Agents Chemother. 54(9), 4012-4015 (2010).
52. Bouza E, Muñoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin. Microbiol. Infect. 10(Suppl. 1), 76-85 (2004).
53. Celik AD, Ozaras R, Kantarcioglu S, Mert A, Tabak F, Ozturk R. Spondylodiscitis due to an emergent fungal pathogen: Blastoschizomyces capitatus, a case report and review of the literature. Rheumatol. Int. 29(10), 1237-1241 (2009).
54. Lapusan S, Dimicoli S, Marjanovic Z et al. Immune reconstitution inflammatory syndrome following Allo-SCT in a patient with Dipodascus capitatus spondylodiscitis. Bone Marrow Transplant. 46(9), 1265-1267 (2010).
55. Bonini A, Capatti C, Parmeggiani M et al. Galactomannan detection in Geotrichum capitatum invasive infections: report of 2 new cases and review of diagnostic options. Diagn. Microbiol. Infect. Dis. 62(4), 450-452 (2008).
56. Martino P, Venditti M, Micozzi A et al. Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev. Infect. Dis. 12(4), 570-582 (1990).
57. Giacchino M, Chiapello N, Bezzio S et al. Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J. Clin. Microbiol. 44(9), 3432-3434 (2006).
58. Venditti M, Posteraro B, Morace G, Martino P. In vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus. J. Chemother. 3(1), 13-15 (1991).
59. Etienne A, Datry A, Gaspar N et al. Successful treatment of disseminated Geotrichum capitatum infection with a combination of caspofungin and voriconazole in an immunocompromised patient. Mycoses 51(3), 270-272 (2008).
60. Ikuta K, Torimoto Y, Yamamoto M et al. Successful treatment of systemic Geotrichum capitatum infection by liposomal amphotericin-B, itraconazole, and voriconazole in a Japanese man. Intern. Med. 49(22), 2499-2503 (2010).
61. Adami F, Scarin M, Pescarini L et al. Successful control of Blastoschizomyces capitatus infection in three consecutive acute leukaemia patients despite initial unresponsiveness to liposomal amphotericin B. Mycoses 54(4), 365-369 (2010).
62. Hajjeh RA, Conn LA, Stephens DS et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J. Infect. Dis. 179(2), 449-454 (1999).
63. Pappas PG, Perfect JR, Cloud GA et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin. Infect. Dis. 33(5), 690-699 (2001).
64. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50(8), 1101-1111 (2010).
65. Baddley JW, Perfect JR, Oster RA et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur. J. Clin. Microbiol. Infect. Dis. 27(10), 937-943 (2008).
66. Almyroudis NG, Segal BH. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Rev. Anti Infect. Ther. 8(12), 1451-1466 (2010).
67. Korfel A, Menssen HD, Schwartz S, Thiel E. Cryptococcosis in Hodgkin's disease: description of two cases and review of the literature. Ann. Hematol. 76(6), 283-286 (1998).
68. Binder U, Lass-Flörl C. Epidemiology of invasive fungal infections in the mediterranean area. Mediterr. J. Hematol. Infect. Dis. 3(1), e20110016 (2011).
69. Zinck SE, Leung AN, Fros M, Berry GJ, Muller NL. Pulmonary cryptococcosis: CT and pathologic findings. J. Comput. Assist. Tomogr. 26, 330-334 (2002).
70. Tanner DC, Weinstein MP, Fedorciw B, Joho KL, Thorpe JJ, Reller L. Comparison of commercial kits for detection of cryptococcal antigen. J. Clin. Microbiol. 32, 1680-1684 (1994).
71. Pagano L, Caira M, Falcucci P, Fianchi L. Fungal CNS infections in patients with hematologic malignancy. Expert Rev. Anti Infect. Ther. 3(5), 775-785 (2005).
72. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 50(3), 291-322 (2010).
73. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr. Opin. Invest. Drugs 4, 179-185 (2003).
74. Tuon FF, Costa SF. Rhodotorula infection. A systematic review of 128 cases from literature. Rev. Iberoam. Micol. 25(3), 135-140 (2008).
75. García-Suárez J, Gómez-Herruz P, Cuadros JA, Burgaleta C. Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses 54(4), 318-324 (2011).
76. Krcmery V, Krupova I, Denning DW. Invasive yeast infections other than Candida spp. in acute leukaemia. J. Hosp. Infect. 41(3), 181-194 (1999).
77. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. Clin. Microbiol. 41(11), 5233-5235 (2003).
78. Kiehn TE, Gorey E, Brown AE, Edwards FF, Armstrong D. Sepsis due to Rhodotorula related to use of indwelling central venous catheters. Clin. Infect. Dis. 14(4), 841-846 (1992).
79. Kappe R, Schulze-Berge A. New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J. Clin. Microbiol. 31, 2489-2490 (1993).
80. Swanink CM, Meis JF, Rijs AJ, Donnelly JP, Verweij PE. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J. Clin. Microbiol. 35, 257-260 (1997).
81. Gomez-Lopez A, Mellado E, Rodriguez- Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J. Antimicrob. Chemother. 55(3), 312-316 (2005).
82. García-Suárez J, Gómez-Herruz P, Cuadros JA, Guillén H, Burgaleta C. Rhodotorula mucilaginosa catheter-related fungaemia in a patient with multiple myeloma. Mycoses 54(4), e214-e216 (2011).
83. Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. Activities of available and investigational antifungal agents against Rhodotorula species. J. Clin. Microbiol. 43(1), 476-478 (2005).
84. Lui AY, Turett GS, Karter DL, Bellman PC, Kislak JW. Amphotericin B lipid complex therapy in an AIDS patient with Rhodotorula rubra fungemia. Clin. Infect. Dis. 27(4), 892-893 (1998).
85. Tuon FF, de Almeida GM, Costa SF. Central venous catheter-associated fungemia due to Rhodotorula spp. - a systematic review. Med. Mycol. 45(5), 441-447 (2007).
86. Lunardi LW, Aquino VR, Zimerman RA, Goldani LZ. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin. Infect. Dis. 43(6), e60-e63 (2006).
87. Krcmery V Jr, Oravcova E, Spanik S et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J. Antimicrob. Chemother. 41(3), 373-380 (1998).
88. Bakir M, Cerikcioǧlu N, Tirtir A, Berrak S, Ozek E, Canpolat C. Pichia anomala fungaemia in immunocompromised children. Mycoses 47(5-6), 231-235 (2004).
89. Blaes AH, Cavert WP, Morrison VA. Malassezia: is it a pulmonary pathogen in the stem cell transplant population? Transpl. Infect. Dis. 11(4), 313-317 (2009).
90. Morrison VA, Weisdorf DJ. The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant. 26(6), 645-648 (2000).
91. Cassone M, Serra P, Mondello F et al. Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism. J. Clin. Microbiol. 41(11), 5340-5343 (2003).